Fragment 176-191 houses the primary proposed ‘lipolytic fragment’ of the growth hormone (hGH) and it potentially targets the beta-3 adrenergic receptors (ADRB3), which may facilitate its suggested weight-loss potential. This peptide is proposed to amplify fat burning in adipose tissue cells and stimulate ‘thermogenesis’ in skeletal muscle cells via these receptors.[1]
CJC-1295 (Mod GRF 1-29), is an apparently enhanced version of GHRH (1-29) crafted to potentially optimize its pharmacokinetics. It is posited to elevate growth hormone and Insulin-Like Growth Factor 1 (IGF-1) levels. Research suggests it may increase growth hormone production between 200-1000%. Furthermore, CJC-1295 is believed to increase plasma IGF-I concentrations by 1.5- to 3-fold.[2]
Ipamorelin, a five-amino-acid chain, is identified as a Growth Hormone Secretagogue (GHS). It is posited to function similarly to Growth Hormone Releasing Peptides (GHRPs) and to apparently emulate the natural hunger hormone, ghrelin, particularly its potential to stimulate the release of hGH from pituitary cells.[3] A notable feature of Ipamorelin research is its apparent selectivity and its reported negligible influence on the secretion of other pituitary hormones like cortisol, prolactin, and aldosterone.
Reviews
There are no reviews yet.